At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 target
Drug / intervention
external beam radiotherapy plus 90-Y ibritumomab tiuxetanother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Role of Conformal External Beam Radiotherapy in the Management of Patients With Bulky Disease Undergoing Y90-Ibritumomab Tiuxetan (Zevalin) Radio-immunotherapy for Indolent B-cell Non-Hodgkin's Lymphoma
In Brief
A Phase 1 clinical trial evaluating external beam radiotherapy plus 90-Y ibritumomab tiuxetan for Lymphoma, B-Cell. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of the research study is to learn whether external beam radiation can be used as a safe and effective treatment for patients with bulky (≥ 5cm) sites of non-Hodgkin's lymphoma prior to treatment with 90Y-ibritumomab tiuxetan (Zevalin).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, B-Cell
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedDec 2005
Primary CompletionDec 2007
Study CompletionJun 2010
TodayJul 2026
First PostedDec 29, 2005
Enrollment StartDec 1, 2005
Primary CompletionDec 1, 2007
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.5 years ago
Interventions
external beam radiotherapy plus 90-Y ibritumomab tiuxetanother
combination of EBRT followed by radioimmunotherapeutic 90-Y ibritumomab tiuxetan